Nuclease Probe Technologies

Curated by Signal

Developer of pathogen detection tests

Overview

Developer of pathogen detection tests. The company has developed a phenotypic antibiotic susceptibility test (AST) which identifies the type of infection from blood samples and suggests the appropriate antibiotic for it. The company is also developing bloodstream pathogen detection tests, urine pathogen detection tests, and nuclease tests for circulating tumor cells.

Key facts

Founded: 2014
Headquarters: Lowell, United States
Stage: Sign up to view
Industry: Health Technology

Contact

Primary office: Sign up to view
Email: Sign up to view

More on Vanberra Signal

Members only

Business overviewCore metrics and financials PeopleLeadership and key people Similar companiesPeers and competitors Deep AnalysisAI-generated strategic report

Competitors & similar companies

More Health Technology companies

CancerLife
Online community of people with cancer
Health TechnologyPhiladelphia, United States
Muscular Discipline
Online platform for the purchase of fitness supplements and accessories
Health TechnologyAmes, United States
Intagras
Pharmaceutical regulatory software solutions.
Health TechnologyTampa, United States

About Nuclease Probe Technologies

What does Nuclease Probe Technologies do?

Developer of pathogen detection tests.

Where is Nuclease Probe Technologies headquartered?

Nuclease Probe Technologies is headquartered in Lowell, United States.

When was Nuclease Probe Technologies founded?

Nuclease Probe Technologies was founded in 2014.

Which sector is Nuclease Probe Technologies in?

Nuclease Probe Technologies operates in Health Technology.

Who are Nuclease Probe Technologies's competitors?

Companies similar to Nuclease Probe Technologies include CancerLife, Muscular Discipline, and Intagras.